Oxidative Medicine and Cellular Longevity

Oxidative Medicine and Cellular Longevity / 2009 / Article

Open Access

Volume 2 |Article ID 795183 | https://doi.org/10.4161/oxim.2.5.9990

Kenneth Maiese, Zhao Zhong Chong, Jinling Hou, Yan Chen Shang, "New Strategies for Alzheimer Disease and Cognitive Impairment", Oxidative Medicine and Cellular Longevity, vol. 2, Article ID 795183, 11 pages, 2009. https://doi.org/10.4161/oxim.2.5.9990

New Strategies for Alzheimer Disease and Cognitive Impairment

Received22 Jul 2009
Revised24 Aug 2009
Accepted02 Sep 2009


Approximately five million people suffer with Alzheimer disease (AD) and more than twenty-four million people are diagnosed with AD, pre-senile dementia, and other disorders of cognitive loss worldwide. Furthermore, the annual cost per patient with AD can approach $200,000 with an annual population aggregate cost of $100 billion. Yet, complete therapeutic prevention or reversal of neurovascular injury during AD and cognitive loss is not achievable despite the current understanding of the cellular pathways that modulate nervous system injury during these disorders. As a result, identification of novel therapeutic targets for the treatment of neurovascular injury would be extremely beneficial to reduce or eliminate disability from diseases that lead to cognitive loss or impairment. Here we describe the capacity of intrinsic cellular mechanisms for the novel pathways of erythropoietin and forkhead transcription factors that may offer not only new strategies for disorders such as AD and cognitive loss, but also function as biomarkers for disease onset and progression.

Copyright © 2009 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Order printed copiesOrder